Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients

Inclusion Criteria: * 18-65 years of age, male or female * 1-5 years after kidney transplantation * The patient has been accepting cyclosporin-based immunosuppressive therapy for ≥6 months, and the therapeutic regimen has kept stable for at least 4 weeks before inclusion * The dose of cyclosporin has kept stable for at least 4 weeks before inclusion * At least one of the cyclosporin-related adverse reactions is present or the answer to the 5th question in the questionnaire is "Yes" at the time of inclusion: * gingival hyperplasia and treatment requested by the patient * polytrichia and interventional therapy requested by the patient * post-transplantation hypertension * post-transplantation hyperlipemia (total cholesterol\>5.7 mmol/L (220 mg/dl)) * Serum creatinine\<200 μmol/l ( 2.3 mg/dl) * A promise is made to take contraceptive measures during the study (women at childbearing ages). Exclusion Criteria: * Patients having accepted transplantation of other organs apart from kidney transplantation * Patients with 24-hour urine protein\>2 g * Patients with SGPT/ALT, SGOT/AST or total bilirubin continually increasing to more than twice the normal value(s) * Patients with refractory infectious foci * Patients with serious diarrhea or vomiting, active upper gastrointestinal ulcers or malabsorption * Patients with serious heart or lung diseases or history of sugar tolerance abnormality or malignant tumors * Patients allergic to tacrolimus or other basic medications * Pregnant or lactating women * Patients having participated in other clinical trials within the previous month * Other patients who are considered by doctors unsuitable for the study